Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluating the Performance of AI in Evaluating Breast MRI Performed With Dose Reduction
NCT04340180Phase 1Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Jul 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-blind, single-arm trial of gadolinium in benign breast tumor and breast cancer, sponsored by University of Alabama at Birmingham. Primary endpoints: Lesion conspicuity on a scale of 1-4, Lesion size in millimeters and 2 more. Started Jul 2021; status: completed.
02
Drugs
gadolinium
03
Conditions
benign breast tumorbreast cancer
Beyond the preview
Go deeper on NCT04340180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04340180.